ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lomustine

Also written as “Lomustine (CCNU)”, “L19TNF and CCNU” and “nab-sirolimus + lomustine”.

Its studies are mostly in Glioblastoma · Glioma, led by 8 companies.

Drug pageLomustine: every studyMany companies study it; this page follows only the 9 they lead. All 46 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jul 30, 20259 company-led studies, 1 open or runningNext primary completion: Jan 30, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Philogenits history only21 open or runningphase 2since Jul 30, 2025Feb 24, 2022Jan 30, 2029phase 2 · NCT07120984
Aadi Bioscienceits history only10 open or runningphase 2since Mar 5, 2018Mar 5, 2018none ahead
Bristol-Myers Squibbits history only10 open or runningphase 2since Jul 28, 2009Jul 28, 2009none ahead
Eli Lillyits history only10 open or runningphase 2since Apr 19, 2012Apr 19, 2012none ahead
Hoffmann-La Roche10 open or runningphase 2since May 21, 2013May 21, 2013none ahead
Karyopharm Therapeuticsits history only10 open or runningphase 2since Jun 1, 2020Jun 1, 2020none ahead
Novartisits history only10 open or runningphase 1since Aug 20, 2013Aug 20, 2013none ahead
Pfizerits history only10 open or runningphase 3since Sep 12, 2003Sep 12, 2003none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 21, 2013First study: phase 2 study in GlioblastomaFirst studyNCT01860638 · 296 enrolled · Austria, Bulgaria, Canada and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01860638Glioblastoma · Austria, Bulgaria, Canada and more2CompletedJan 13, 2017296

How it is read

Names in the registry

  • “Lomustine”, 4 entries
  • “Lomustine (CCNU)”, 2 entries
  • “L19TNF and CCNU”, 1 entry
  • “nab-sirolimus + lomustine”, 1 entry
  • “lomustine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.